Tevogen Inc. (TVGN): Total Liabilities
$12.62M
As of 2025-12-31
$13.62M
As of 2026-06-30
-5.7%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.62M | +24.5% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $10.14M | -89.9% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $99.93M | +563.7% | 2025-04-02, Balance as of period end |
| 2022-12-31 | $15.06M | -0.8% | 2024-04-29, Balance as of period end |
| 2021-12-31 | $15.18M | n/a | 2023-04-17, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Tevogen Inc. (TVGN) | 2025-12-31 | $12.62M | +24.5% |
| Eloxx Pharmaceuticals, Inc. (ELOX) | 2025-12-31 | $17.18M | -37.1% |
| Cero Therapeutics Holdings, Inc. (CERO) | 2025-12-31 | $9.09M | +12.2% |
| BioCardia, Inc. (BCDA) | 2025-12-31 | $2.52M | -12.8% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $15.56M | +56.7% |
| Exozymes Inc. (EXOZ) | 2025-12-31 | $2.57M | -1.5% |
| Estrella Immunopharma, Inc. (ESLA) | 2025-12-31 | $13.54M | +351.9% |
| Silexion Therapeutics Corp (SLXN) | 2025-12-31 | $4.61M | -32.7% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $8.48M | +104.1% |
Compare TVGN, ELOX, CERO, BCDA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗